Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Niacin ER in Metabolic Syndrome
NCT00300365Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Nov 2005
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic syndrome comparing Active Pioglitazone + Open-Label Niacin with Placebo + Open-Label Niacin (2 arms). Primary endpoint: High Density Lipoprotein Cholesterol at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
pioglitazone
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT00300365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300365.